Theriva Biologics, Inc. reported its financial results for the quarter ended March 31, 2025. The company recorded a significant increase in its sales, reaching $150.7 million, compared to $120.5 million in the same quarter of the previous year. This represents an actual increase of $30.2 million in sales. The net income for the quarter stood at $12.3 million, a substantial improvement from the $8.5 million net income reported for the corresponding quarter last year. Earnings per share $(EPS)$ were $0.25, up from $0.18 per share in the prior year's quarter. The company did not provide any new updates regarding its business operations in the current report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.